H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals to CHF 28 from CHF 24 and keeps a Buy rating on the shares after the FDA approved Agamree the treatment of Duchenne muscular dystrophy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>